Skip to main content
Professional Technical IVT

monoclonal antibody therapy

Also written as: mAb — monoclonal antibody

Treatment using laboratory-produced antibodies designed to target specific cancer cell antigens.

Full Definition

Monoclonal antibody therapy represents a targeted treatment approach using laboratory-manufactured antibodies that bind to specific antigens expressed on cancer cells. These therapies can work through various mechanisms including direct cell killing, immune system activation, delivery of cytotoxic agents, or blockade of growth signals. Examples in hematologic oncology include rituximab for CD20-positive lymphomas, daratumumab for multiple myeloma, and alemtuzumab for certain leukemias. The specificity of monoclonal antibodies allows for targeted therapy with potentially fewer side effects compared to traditional chemotherapy, though unique toxicities such as infusion reactions and tumor lysis syndrome can occur.

Usage

Usage note: Hyphenate as compound modifier; abbreviate as mAb in appropriate contexts

In Context

  • "Monoclonal antibody therapy with rituximab significantly improved outcomes in diffuse large B-cell lymphoma." — Clinical trial results
  • "The development of monoclonal antibody therapy revolutionized treatment approaches in hematologic malignancies." — Review article

Also known as

mAb therapy targeted antibody therapy

Contrasted with

chemotherapy broad-spectrum therapy

Don't confuse with

polyclonal antibody immunoglobulin therapy

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON